PT-141, or bremelanotide, is described as a melanocortin receptor agonist studied in sexual-desire signalling. United States labelling for the approved formulation is narrow: acquired, generalized hypoactive sexual desire disorder in premenopausal women, with stated exclusions, and it notes the mechanism for that indication is not fully known. US bremelanotide prescribing information
Mechanism, stated honestly
The compound acts at melanocortin receptors. Labelling does not present a fully established pathway for the treated condition, so descriptions claiming a precise, proven mechanism go beyond the source. US bremelanotide prescribing information
What the approved indication covers
The approved United States indication is specific to acquired, generalized hypoactive sexual desire disorder in premenopausal women, with exclusions stated in the label. It is not indicated for men, not for postmenopausal women, and not for performance enhancement. US bremelanotide prescribing information
Balanced safety context
The label describes transient increases in blood pressure, nausea, and hyperpigmentation among relevant considerations. A summary that omits these is incomplete rather than concise. US bremelanotide prescribing information
| Item | Detail |
|---|---|
| Approved product | A specific United States formulation with a defined indication and labelling. |
| Research material | Laboratory-use material; not the approved product and not authorized as a medicine. |
| Canadian status | Not asserted here; verify in the Health Canada Drug Product Database. |
Study context and limits
- Label information describes the approved formulation, not a research vial.
- United States labelling implies nothing about Canadian authorization.
- The mechanism for the labelled indication is described as not fully known.
US bremelanotide prescribing information Health Canada Drug Product Database
Reading checklist
- Quote the indication in full, including its population limits.
- Include blood-pressure, nausea and pigmentation considerations in any summary.
- Do not extend a labelled indication to other populations or to enhancement.
- Keep approved-product facts separate from research-material facts.
An ingredient name is not a finished, approved formulation
Short answer: an ingredient name and an approved branded medicine are different things. Approved labelling describes a specific formulation, a defined strength, presentation, manufacturing process and authorised use. A research-listing name that matches the ingredient does not inherit any of that.
| Item | Detail |
|---|---|
| Approved product | A named formulation assessed by a regulator, with labelling that states strength, presentation and authorised use. |
| Ingredient-name match | Only that a name matches. It carries no assessment, no formulation equivalence and no authorisation. |
| What labelling can be used for | Understanding how the described mechanism and endpoints were characterised for that approved product. |
| What it cannot be used for | Treating a research listing as equivalent, assessed, or authorised. |
This is the same reasoning that applies to searching a regulator's product database: finding an ingredient name there tells you an authorised product exists containing that ingredient. It says nothing about unrelated research material bearing the same name. US bremelanotide prescribing information Health Canada Drug Product Database
Frequently asked
Is PT-141 approved for men?
The United States approved indication covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with exclusions. It is not indicated for men.
Is its mechanism fully understood?
Labelling describes melanocortin receptor agonism but states that the mechanism for the labelled indication is not fully known.
Does US labelling mean it is authorized in Canada?
No. Canadian authorization is a separate question to check in Health Canada’s Drug Product Database.
References
Each reference describes a particular study or document. It does not verify any Proof Line Peptides lot, and it does not indicate that a product is authorized for sale in Canada.
- Official United States prescribing information for bremelanotide injection (Vyleesi), revised March 2024. United States labelling only. View source
- Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada. View source
